Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 1,380.69 | 1,427.30 | 1,423.66 | 1,369.98 | 1,189.33 |
Total Expenses | 1,417.94 | 1,500.16 | 1,370.73 | 1,224.53 | 1,095.26 |
Profit Before Tax | -54.65 | -137.66 | 52.93 | 136.63 | 94.08 |
Profit After Tax | -29.61 | -121.98 | 44.76 | 104.45 | 82.05 |
Operating Profit after Depreciation | 10.83 | -37.35 | 68.70 | 169.84 | 129.79 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 596.80 | 609.21 | 567.26 | 537.66 | 578.93 |
Total Non Current Assets | 729.45 | 749.33 | 667.79 | 678.97 | 758.51 |
Total Current Assets | 810.94 | 779.79 | 783.18 | 713.59 | 704.14 |
TOTAL ASSETS | 1,540.38 | 1,529.12 | 1,450.97 | 1,392.56 | 1,462.65 |
Total Shareholder's Fund | 656.56 | 698.78 | 692.10 | 727.65 | 687.10 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 30.60 | 16.81 | 30.60 | 114.75 | 115.33 |
Net Cash used in Investing Activities | -5.92 | -64.96 | -94.10 | 9.65 | -72.27 |
Net Cash used in Financing Activities | -1.44 | 32.23 | 67.26 | -138.75 | -42.75 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 214.50 | 250.93 | 247.27 | 285.42 | 241.89 |
Total Expenses | 208.48 | 260.67 | 231.58 | 241.98 | 219.08 |
Profit Before Tax | -0.24 | -9.75 | 15.69 | 40.89 | 22.81 |
Profit After Tax | 0.62 | -6.08 | 14.80 | 32.11 | 21.34 |
Operating Profit after Depreciation | 10.38 | -7.23 | 17.30 | 46.13 | 27.85 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 42.52 | 56.72 | 66.90 | 65.78 | 69.41 |
Total Non Current Assets | 1,090.82 | 1,047.75 | 978.37 | 983.56 | 885.70 |
Total Current Assets | 96.78 | 75.02 | 145.86 | 118.56 | 111.67 |
TOTAL ASSETS | 1,187.60 | 1,122.77 | 1,124.23 | 1,102.12 | 997.37 |
Total Shareholder's Fund | 1,087.23 | 1,058.36 | 1,041.09 | 1,029.51 | 886.22 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | -26.94 | 37.75 | 9.36 | 2.34 | 30.20 |
Net Cash used in Investing Activities | 5.47 | -50.70 | -4.25 | 16.55 | -17.69 |
Net Cash used in Financing Activities | 22.32 | 0.24 | 7.25 | -21.33 | -10.71 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 368.65 | 390.21 | 361.20 | 329.36 | 345.97 |
Total Expenses | 329.55 | 348.26 | 328.93 | 307.11 | 330.84 |
Profit Before Tax | 7.90 | 12 | 2.64 | 1.49 | -3.09 |
Profit After Tax | 6.34 | 9.06 | 1.27 | 10.68 | -6.88 |
Operating Profit after Depreciation | 43.61 | 44.63 | 36.27 | 26.77 | 16.78 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 41.99 | 57.67 | 36.77 | 42.21 | 49.12 |
Total Expenses | 44.09 | 59.65 | 42.53 | 46.36 | 56.82 |
Profit Before Tax | 6.41 | 6.05 | 4.10 | 6.09 | -1.39 |
Profit After Tax | 4.26 | 4.50 | 3.76 | 4.58 | -0.92 |
Operating Profit after Depreciation | 13.85 | 8.86 | 7.22 | 9.29 | 2.17 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Sequent Scientific Ltd | ₹177 | ₹4,430.35 |
Sun Pharmaceuticals Industries Ltd | ₹1,761.80 | ₹4,22,714.84 |
Divis Laboratories Ltd | ₹5,818.40 | ₹1,54,460.24 |
Cipla Ltd | ₹1,427.30 | ₹1,15,270.75 |
Dr Reddys Laboratories Ltd | ₹1,288.45 | ₹1,07,511.36 |
Torrent Pharmaceuticals Ltd | ₹3,157.60 | ₹1,06,862.73 |
22 Jan 2025, 01:56 pm
25 Nov 2024, 03:52 pm
22 Nov 2024, 05:48 pm
07 Nov 2024, 08:06 pm
30 Oct 2024, 11:44 am